CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 450 enrolled
Drug / intervention
Experimental: Test Product 1 +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04800211
NCT04800211N/ACompleted
CompareCT.gov

An Open-Label, Parallel-Group, Controlled Study to Evaluate Changes in Biomarkers of Cigarette Smoke Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely Switch to Using e-Vapor Products for 24 Weeks

Altria Client Services LLC·interventional·Posted Mar 16, 2021·Updated Mar 12, 2025

In Brief

A clinical study evaluating Experimental: Test Product 1 and Experimental: Test Product 2 for Tobacco Use. Completed, enrolled 450 participants across 10 sites.

Detailed Summary

The purpose of this study was to estimate changes in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in adult cigarette smokers (AS) who switched to using an e-vapor product (EVP) relative to adult smokers who continue smoking exclusively.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 16, 2021
Enrollment StartJan 17, 2017
Primary CompletionJul 20, 2018
Study CompletionNov 6, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.3 years ago

Interventions

Experimental: Test Product 1other

Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)

Experimental: Test Product 2other

Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)